Targeting TET Enzymes for Blood Cancers
Targeting TET DNA Dioxygenases as Therapeutic Principle in Myeloid Neoplasms
This research explores new ways to treat blood cancers like myelodysplastic syndromes (MDS) by focusing on specific enzymes called TET, which play a role in how these diseases develop.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11123910 on NIH RePORTER |
What this research studies
TET enzymes are crucial for healthy cell function, particularly in how our DNA is regulated. Many individuals with blood cancers, including MDS, have changes in one of these enzymes, known as TET2. These changes can contribute to the early stages of blood disorders and even more aggressive forms of cancer. This project aims to understand precisely how these TET enzymes work and how their alterations lead to blood cancers. By gaining this understanding, we hope to discover new treatment strategies that specifically target these enzymes to stop the disease from progressing or potentially prevent it.
Who could benefit from this research
Good fit: Patients with myeloid neoplasms, especially those with TET2 mutations, could potentially benefit from future treatments developed from this research.
Not a fit: Patients without myeloid neoplasms or related hematologic malignancies may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to new medications or therapies for patients with myeloid neoplasms, potentially improving treatment outcomes or preventing disease progression.
How similar studies have performed: Some related approaches targeting similar cellular pathways have shown promise in other conditions, and early findings in mouse models support this direction.
Where this research is happening
Cleveland, United States
- Cleveland Clinic Lerner Com-Cwru — Cleveland, United States (Active)
Researchers
- Principal investigator: Maciejewski, Jaroslaw P. — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Maciejewski, Jaroslaw P.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.